Clinical pharmacology of topiramate in migraine prevention

Abstract

Topiramate is an important option for the prophylaxis of migraine and is of proven efficacy and tolerability. It has also been studied in chronic migraine with encouraging results, even in patients with medication overuse. However, in migraine prevention its efficacy is comparable to the other first-line drugs and there are no published trials with a superiority design which can establish topiramate's role in the available therapeutic armamentarium.

Synthesis and Human Carbonic Anhydrase I, II, IX, and XII Inhibition Studies of Sulphonamides Incorporating Mono-, Bi- and Tricyclic Imide Moieties

“…Some of the sulphonamides are better than these clinically used hCA inhibitors ( Table 2 ). Further pre-clinical and clinical trials are required to test these potent hCA inhibitors for their clinical importance [ 2 , 33 , 34 , 35 , 36 ]. Patients affected by COVID-19 could show a dysregulated acid–base status probably influenced by the CA activity, which is highly increased in patients affected by COVID-19 infection.…”

Применение Лекарственного Мониторинга Топирамата Для Индивидуализации Превентивной Антимигренозной Терапии

“… ñâîþ î÷åðåäü, ïðèìåíåíèå ïðåïàðàòà â äîçå 50 ìã/ñóò õàðàêòåðèçóåòñÿ áîëåå íèçêèì ÷èñëîì ÂÏ (39 %), íî ïðåâûøàåò òàêîâîå äëÿ ïëàöåáî (29 %).  ýòîé ñâÿçè ñóòî÷íàÿ äîçà 100 ìã ñ÷èòàåòñÿ îïòèìàëüíîé äëÿ ïðîôèëàêòèêè ïðèñòóïîâ ìèãðåíè êàê íàèáîëåå ýôôåêòèâíàÿ è õîðîøî ïåðåíîñèìàÿ [15]. Ðåêîìåíäóåòñÿ íà÷èíàòü ëå÷åíèå ñ 25 ìã/ñóò, íàðàùèâàÿ äîçó ñ øàãîì â 25 ìã â íåäåëþ äî 100 -200 ìã/ñóò.…”

Drug-induced retroperitoneal fibrosis: short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology

“…Subsequently nonergot-derived anti-migraine drugs were used ,among which particularly sumatriptan, as a serotonin 5-HT1-line receptor agonist together with 5-HT2A/5-HT2C receptor antagonism, it inducing a negative feedback regulation of brain serotonin synthesis , and topiramate, as a blocker of brain cell voltage-dependent sodium channels togheter with enhancing the GABA (γ-amino-butyric acid) activity at related receptors while antagonizing the glutamate pathway (19)(20)(21).…”